Growth Metrics

Vynleads (VYND) Revenue (2020 - 2022)

Vynleads (VYND) reported Revenue of $49.0 for Q2 2022, down 75.86% year-over-year from $203.0 in Q2 2021, and down 75.86% on a QoQ basis from $203.0 in Q2 2021.

Vynleads (VYND) has 3 years of Revenue data on file, last reported at $49.0 in Q2 2022.

  • Quarterly Revenue fell 75.86% year-over-year to $49.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $49.0 (changed N/A YoY) and the FY2022 annual result came in at $49.0, down 89.88% from the prior year.
  • Revenue fell to $49.0 in Q2 2022 per VYND's latest filing, from $203.0 in the prior quarter.
  • Across five years, Revenue topped out at $23388.0 in Q1 2020 and bottomed at $49.0 in Q2 2022.
  • The 3-year median for Revenue is $770.0 (2020), against an average of $6970.7.
  • The widest annual swing landed in 2021, when Revenue plunged 98.8%; it then plunged 75.86% in 2022.
  • Tracing VYND's Revenue over 3 years: stood at $770.0 in 2020, then slumped by 73.64% to $203.0 in 2021, then sank by 75.86% to $49.0 in 2022.
  • Per Business Quant, the three latest VYND Revenue figures stand at $49.0 (Q2 2022), $203.0 (Q2 2021), and $281.0 (Q1 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn 835.95 Mn
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 3.61 Bn
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 354.64 Mn
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn 182.31 Mn
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn 145.37 Mn
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 313.87 Mn
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn 150.84 Mn
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn 603.85 Mn
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn 309.88 Mn
10 Vynleads - - -2,028.00 -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 49.00
Jun 30, 2021 203.00
Mar 31, 2021 281.00
Dec 31, 2020 770.00
Sep 30, 2020 8,379.00
Jun 30, 2020 15,725.00
Mar 31, 2020 23,388.00